Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Co.don AG. (5/15/14). "Press Release: Successful Capital Increase. All Available Shares Successfully Sold – Capital Increase Oversubscribed by 72%".

Region Region Germany
Organisations Organisation Co.don AG
  Group Co.don (Group)
  Organisation 2 Frankfurt Stock Exchange (FSE)
  Group Deutsche Börse (Group)
Products Product chondrosphere®
  Product 2 chondrotransplant® DISC method
Index term Index term Co.don–SEVERAL: investment, 201405 capital increase €5m 2.6m new shares €1.9/share
Persons Person Baltrusch, Andreas (Co.don 201202 CEO)
  Person 2 Methner, Vilma (Co.don 201405 COO + CSO)

The biopharma company co.don® AG, listed on the General Standard of the Frankfurt Stock Exchange, (ISIN: DE000A1K0227/ WKN A1K022) has successfully completed a capital increase for subscription in cash from authorised capital.

By making use of the authorised capital created by the shareholders' meeting on 7 August 2013 the share capital was increased by cash subscriptions from €11,108,584 by €2,613,784 to €13,722,368 for the issue of 2,613,784 new bearer shares at a price of €1.90 per share. Shareholders were offered the new shares by way of an indirect rights issue. Shareholders were also entitled to place orders for additional new shares at the issue price when exercising their subscription rights. The subscription period began on 28 April 2014 and ended on 13 May 2014.

Shares not purchased by shareholders during this period were offered for sale to third parties on the same terms as part of a private placement.

In total, subscription requests were received for 4,503,978 shares. This oversubscription meant that not enough new shares were available to satisfy all the requests from existing shareholders and the private placement, so both groups of investors were treated equally.

"I am very pleased by this vote of confidence from both our existing and our new investors, to whom I would like to extend a particularly warm welcome. The oversubscription shows the strong level of interest in our company", said Dr. Andreas Baltrusch, CEO of co.don® AG.

The proceeds of the capital increase are mainly to be used to carry out further clinical trials to obtain central EU-wide approval for the cell-based pharmaceutical product chondrosphere®. In addition, co.don® AG has a method of cultivating autologous disc cells for the regenerative treatment of herniated vertebral discs known as co.don chondrotransplant® DISC. The issue proceeds are also intended to enable preliminary work relevant to its approval process to be carried out.

biw Bank für Investments und Wertpapiere AG, Willich, acted as the subscription agent, SCHNIGGE Wertpapierhandelsbank AG was responsible for the placement of the shares not purchased by existing shareholders.

About co.don® AG:

The biopharmaceutical company is one of the leading specialists worldwide in cell cultivation for the regenerative treatment of articular cartilage defects and spinal disc defects. In many cases the use of the company's patented pharmaceutical product can avert the need for joint and spinal disc replacement surgery. Orthopaedic, accident and neuro-surgeons are increasingly applying these regenerative treatment methods. co.don® AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). The company's Executive Board consists of Dr. Andreas Baltrusch (CEO, CFO) and Ms Vilma Methner (COO, CSO).

Further information about co.don AG can be found at: and


Matthias Meißner, M.A.
Investor relations

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Co.don (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top